EU/3/13/1139

About

On 19 June 2013, orphan designation (EU/3/13/1139) was granted by the European Commission to Shore Limited, United Kingdom, for sodium chlorite (also known as NP001) for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to FGK Representative Services GmbH, Germany in December 2017.

Key facts

Active substance
Sodium chlorite
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of decision
19/06/2013
Outcome
Positive
Orphan decision number
EU/3/13/1139

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

FGK Representative Services GmbH
Heimeranstrasse 35
80339 Munich
Germany
Tel. +49 89 89 31 19 22
E-mail: info@fgk-rs.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating
Average
2 ratings